{"description":"Documents matching 'compliance certain emergency medical treatment'","count":4939,"total_pages":50,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=compliance+certain+emergency+medical+treatment&format=json&page=2","results":[{"title":"Registering Emergency Medical Services Agencies Under the Protecting Patient Access to Emergency Medications Act of 2017","type":"Rule","abstract":"The \"Protecting Patient Access to Emergency Medications Act of 2017,\" (the Act) which became law on November 17, 2017, amended the Controlled Substances Act (CSA) to allow for a new registration category for emergency medical services agencies that handle controlled substances. It also established standards for registering emergency medical services agencies, and set forth new requirements for delivery, storage, and recordkeeping related to their handling of controlled substances. In addition, the Act allows emergency medical services professionals to administer controlled substances outside the physical presence of a medical director or authorizing medical professional pursuant to a valid standing or verbal order. The Drug Enforcement Administration is publishing this final rule to conform its regulations to the statutory amendments of the CSA and to otherwise implement its requirements. This final rule adopts, with minor modifications, the notice of proposed rulemaking published on October 5, 2020.","document_number":"2026-02288","html_url":"https://www.federalregister.gov/documents/2026/02/05/2026-02288/registering-emergency-medical-services-agencies-under-the-protecting-patient-access-to-emergency","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-05/pdf/2026-02288.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-02288.pdf?1770153307","publication_date":"2026-02-05","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"the <span class=\"match\">emergency</span> <span class=\"match\">medical</span> services agency is registered and may house EMS vehicles at its premises and is actively and primarily being used by that <span class=\"match\">emergency</span> <span class=\"match\">medical</span> services agency. \n • The provisions outlined in § 1301.80(b) specify when an EMS vehicle storing controlled substances must be locked. An <span class=\"match\">emergency</span> <span class=\"match\">medical</span> services vehicle storing controlled substances must be locked when parked outside of an enclosed registered or designated location, or when it is actively in use and left unattended during non-<span class=\"match\">emergency</span> stops. An <span class=\"match\">emergency</span> <span class=\"match\">medical</span> services"},{"title":"Medical Billing for Healthcare Services Provided by Department of Defense Military Medical Treatment Facilities to Civilian Non-Beneficiaries","type":"Rule","abstract":"As required by the James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 (NDAA-23), this rule reduces financial harm to civilians who are not covered beneficiaries of the Military Health System (MHS), and who receive healthcare services at DoD military medical treatment facilities (MTF). The rulemaking implements the MHS Modified Payment and Waiver Program (MPWP) through which the DoD applies a sliding fee scale and/or a catastrophic fee waiver to medical invoices of certain non-beneficiaries and accepts payments from health insurers of non-beneficiaries as full payment except for copays, coinsurance, deductibles, nominal fees and non- covered services.","document_number":"2026-02437","html_url":"https://www.federalregister.gov/documents/2026/02/06/2026-02437/medical-billing-for-healthcare-services-provided-by-department-of-defense-military-medical-treatment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-02-06/pdf/2026-02437.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-02437.pdf?1770299125","publication_date":"2026-02-06","agencies":[{"raw_name":"DEPARTMENT OF DEFENSE","name":"Defense Department","id":103,"url":"https://www.federalregister.gov/agencies/defense-department","json_url":"https://www.federalregister.gov/api/v1/agencies/103","parent_id":null,"slug":"defense-department"},{"raw_name":"Office of the Secretary"}],"excerpts":"promulgates a rule \n \n that imposes substantial direct <span class=\"match\">compliance</span> costs on one or more Indian Tribes, preempts Tribal law, or effects the distribution of power and responsibilities between the Federal Government and Indian Tribes. This final rule will not have a substantial effect on Indian Tribal Governments.\n \n \n List of Subjects in 32 CFR Part 220 \n Accounts receivable, Civilian <span class=\"match\">medical</span> debt, Claims, Health care, Health insurance, <span class=\"match\">Medical</span> billing, <span class=\"match\">Medical</span> debt, <span class=\"match\">Medical</span> debt waiver, Military <span class=\"match\">medical</span> <span class=\"match\">treatment</span> facilities, Military personnel, and Third party"},{"title":"Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems; and Quality Reporting Programs; Including the Hospital Outpatient Quality Reporting Program and Ambulatory Surgical Center Quality Program; Request for Information on Strengthening the Standardization and Comparability of Hospital Price Transparency (HPT) Data; Prior Authorization; Accrediting Organization (AO) Deeming for Emergency Medical Treatment and Labor Act (EMTALA); and Notices of Closure of Teaching Hospitals and Opportunities To Apply for Available Slots","type":"Proposed Rule","abstract":"This proposed rule would revise the Medicare Hospital Outpatient Prospective Payment System (OPPS) and the Medicare Ambulatory Surgical Center (ASC) payment system for calendar year 2027 based on our continuing experience with these systems. We also describe the changes to the amounts and factors used to determine the payment rates for Medicare services paid under the OPPS and those paid under the ASC payment systems. In addition, this proposed rule would update and refine the requirements for the Hospital Outpatient Quality Reporting Program and the Ambulatory Surgical Center Quality Reporting Program. There are no changes to the Rural Emergency Hospital Quality Reporting Program. We propose to expand the prior authorization requirement to include additional Botulinum Toxin Injection services. We also propose to implement certain provisions of the Consolidated Appropriations Act, 2026, for off-campus outpatient departments of a provider. In addition, this proposed rule announces notices of closure of teaching hospitals and opportunities to apply for available slots. This rule also requests information regarding potential approaches to improve comparability and standardization, particularly for complex contracting methodologies, of the HPT information reported in machine- readable files and consumer-friendly displays. We propose hospital AOs with deeming authority to assess compliance with certain Emergency Medical Treatment and Labor Act (EMTALA) administrative requirements during accreditation and reaccreditation surveys. Finally, we are soliciting comments on a potential separate payment under the Inpatient Prospective Payment System (IPPS) for domestic procurement of personal protective equipment and essential medicines.","document_number":"2026-13656","html_url":"https://www.federalregister.gov/documents/2026/07/07/2026-13656/medicare-program-hospital-outpatient-prospective-payment-and-ambulatory-surgical-center-payment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-07/pdf/2026-13656.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13656.pdf?1782996328","publication_date":"2026-07-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Centers for Medicare & Medicaid Services","name":"Centers for Medicare & Medicaid Services","id":45,"url":"https://www.federalregister.gov/agencies/centers-for-medicare-medicaid-services","json_url":"https://www.federalregister.gov/api/v1/agencies/45","parent_id":221,"slug":"centers-for-medicare-medicaid-services"}],"excerpts":"code 99281 (<span class=\"match\">Emergency</span> department visit for the evaluation and management of a patient (Level 1)); CPT code 99282 (<span class=\"match\">Emergency</span> department visit for the evaluation and management of a patient (Level 2)); CPT code 99283 (<span class=\"match\">Emergency</span> department visit for the evaluation and management of a patient (Level 3)); CPT code 99284 (<span class=\"match\">Emergency</span> department visit for the evaluation and management of a patient (Level 4)); CPT code 99285 (<span class=\"match\">Emergency</span> department visit for the evaluation and management of a patient (Level 5)) or HCPCS code G0380 (Type B <span class=\"match\">emergency</span> department"},{"title":"TRICARE Coverage of Clinical Trials and Termination of Expanded Access Treatments","type":"Rule","abstract":"The Assistant Secretary of Defense for Health Affairs (ASD(HA)) issues this final rule regarding circumstances under which services and supplies related to emerging treatments may be covered under the TRICARE program. This rule finalizes provisions published in two interim final rules (IFRs) with request for comment, which temporarily added coverage for the treatment use of investigational drugs under U.S. Food and Drug Administration (FDA)-authorized expanded access (EA) programs when for the treatment of coronavirus disease 2019 (COVID-19) and permitted coverage of National Institute of Allergy and Infectious Disease (NIAID)-sponsored clinical trials for the treatment or prevention of COVID-19. This final rule discusses the DoD's decision not to make permanent the coverage of treatment use of investigational drugs under FDA EA programs while updating language for care associated with their administration and broadens the COVID-19 clinical trial benefit to include coverage of clinical trials sponsored or approved by any National Institutes of Health (NIH) Center or Institute to treat or prevent infectious diseases associated with a pandemic or epidemic. Lastly, the final rule expands TRICARE's clinical trial benefit by covering services and supplies provided in conjunction with Phase I, II, III, and IV clinical trials that are NIH-sponsored or approved and that involve a new treatment or cure for a specific condition or the treatment of a currently uncontrolled symptom or aspect of that condition, provided that the condition is severely debilitating, life- threatening, or a rare disease.","document_number":"2025-14206","html_url":"https://www.federalregister.gov/documents/2025/07/28/2025-14206/tricare-coverage-of-clinical-trials-and-termination-of-expanded-access-treatments","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-07-28/pdf/2025-14206.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-14206.pdf?1753447522","publication_date":"2025-07-28","agencies":[{"raw_name":"DEPARTMENT OF DEFENSE","name":"Defense Department","id":103,"url":"https://www.federalregister.gov/agencies/defense-department","json_url":"https://www.federalregister.gov/api/v1/agencies/103","parent_id":null,"slug":"defense-department"},{"raw_name":"Office of the Secretary"}],"excerpts":"coverage of <span class=\"match\">treatment</span> use of investigational drugs under FDA EA programs for the <span class=\"match\">treatment</span> of COVID-19 permanent and on permanently covering the drugs for all diseases. No comments were received specific to the coverage of <span class=\"match\">treatment</span> use of investigational drugs on a permanent basis, either for the <span class=\"match\">treatment</span> of COVID-19 or for the <span class=\"match\">treatment</span> of other diseases. This final rule clarifies the DoD's decision not to add permanent coverage of investigational drugs authorized for <span class=\"match\">treatment</span> use under FDA EA programs when prescribed for the <span class=\"match\">treatment</span> of COVID-19"},{"title":"Medical Billing for Healthcare Services Provided by Department of Defense Military Medical Treatment Facilities to Civilian Non-Beneficiaries","type":"Proposed Rule","abstract":"As required by the James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 (NDAA-23), this document proposes to reduce financial harm to civilians who are not covered beneficiaries of the Military Health System (MHS), and who receive healthcare services at DoD military medical treatment facilities (MTF). The rulemaking, once finalized, will implement the MHS Modified Payment and Waiver Program (MPWP) through which the DoD will apply a sliding fee scale and/or a catastrophic fee waiver to medical invoices of certain non-beneficiaries and will accept payments from health insurers of non-beneficiaries as full payment except for copays, coinsurance, deductibles, nominal fees and non-covered services.","document_number":"2024-22584","html_url":"https://www.federalregister.gov/documents/2024/10/01/2024-22584/medical-billing-for-healthcare-services-provided-by-department-of-defense-military-medical-treatment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-10-01/pdf/2024-22584.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-22584.pdf?1727700348","publication_date":"2024-10-01","agencies":[{"raw_name":"DEPARTMENT OF DEFENSE","name":"Defense Department","id":103,"url":"https://www.federalregister.gov/agencies/defense-department","json_url":"https://www.federalregister.gov/api/v1/agencies/103","parent_id":null,"slug":"defense-department"},{"raw_name":"Office of the Secretary"}],"excerpts":"promulgates a rule that imposes substantial direct <span class=\"match\">compliance</span> costs on one or more Indian tribes, preempts tribal law, or effects the distribution of power and responsibilities between the Federal Government and Indian tribes. This proposed rule will not have a substantial effect on Indian tribal governments. \n \n List of Subjects in 32 CFR Part 220 \n Accounts receivable, Civilian <span class=\"match\">medical</span> debt, Claims, Healthcare, Health insurance, <span class=\"match\">Medical</span> billing, <span class=\"match\">Medical</span> debt, <span class=\"match\">Medical</span> debt waiver, Military <span class=\"match\">medical</span> <span class=\"match\">treatment</span> facilities, Military personnel, and Third party"},{"title":"Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment","type":"Rule","abstract":"The \"Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 (the SUPPORT Act),\" which became law on October 24, 2018, amended the Controlled Substances Act to expand the conditions a practitioner must meet to provide medication-assisted treatment for opioid use disorder and expand the options available for a physician to be considered a qualifying physician. The SUPPORT Act also allowed a pharmacy to deliver prescribed controlled substances to a practitioner's registered location for the purpose of maintenance or detoxification treatment to be administered under certain conditions by a practitioner. The Drug Enforcement Administration promulgated an interim final rule with request for comments in November 2020 to amend its regulations to make them consistent with the SUPPORT Act and implement its requirements. On December 29, 2022, the Restoring Hope for Mental Health and Well-Being Act of 2022 removed many of the statutory provisions of the SUPPORT Act. This final rule adopts the provisions of the interim final rule that are still applicable as final, with minor changes. In addition, this final rule implements the related provisions of the Restoring Hope for Mental Health and Well-Being Act of 2022.","document_number":"2026-11526","html_url":"https://www.federalregister.gov/documents/2026/06/09/2026-11526/implementation-of-the-substance-use-disorder-prevention-that-promotes-opioid-recovery-and-treatment","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-09/pdf/2026-11526.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-11526.pdf?1780922715","publication_date":"2026-06-09","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"823(h) by the <span class=\"match\">Medical</span> Marijuana and Cannabidiol Research Expansion Act, 117 Public Law 215 § 103 (2022).\n \n \n \n \n 2 \n  This requirement was incorporated into the CSA by the Narcotic <span class=\"match\">Treatment</span> Act of 1974 (NATA), 93 P.L. 281 § 3 (1974).\n \n \n \n \n 3 \n  21 U.S.C. 802(29) defines \n maintenance <span class=\"match\">treatment</span> \n as the dispensing, for a period in excess of twenty-one days, of a narcotic drug in the <span class=\"match\">treatment</span> of an individual for dependence upon heroin or other morphine-like drugs.\n \n \n \n \n 4 \n  21 U.S.C. 802(30) defines \n detoxification <span class=\"match\">treatment</span> \n as the dispensing"},{"title":"Catastrophic Health Emergency Fund","type":"Rule","abstract":"The Indian Health Service (IHS or Service) administers the Catastrophic Health Emergency Fund (CHEF) pursuant to section 202 of the Indian Health Care Improvement Act (IHCIA). The purpose of the CHEF is to meet the extraordinary medical costs associated with the treatment of victims of disasters or catastrophic illnesses who are within the responsibility of the Service. This document finalizes the regulations governing the administration of the CHEF, with clarifying edits, and responds to comments received on the proposed rule.","document_number":"2024-19421","html_url":"https://www.federalregister.gov/documents/2024/08/30/2024-19421/catastrophic-health-emergency-fund","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-08-30/pdf/2024-19421.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-19421.pdf?1724935517","publication_date":"2024-08-30","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Indian Health Service","name":"Indian Health Service","id":237,"url":"https://www.federalregister.gov/agencies/indian-health-service","json_url":"https://www.federalregister.gov/api/v1/agencies/237","parent_id":221,"slug":"indian-health-service"}],"excerpts":"not be eligible for reimbursement for the cost of <span class=\"match\">treatment</span> from the CHEF until its cost of treating any victim of such catastrophic illness or disaster has reached a <span class=\"match\">certain</span> threshold cost; (3) establishes a procedure for reimbursement of the portion of the costs for authorized services that exceed such threshold costs; (4) establishes a procedure for payment from the CHEF for cases in which the exigencies of the <span class=\"match\">medical</span> circumstances warrant <span class=\"match\">treatment</span> prior to the authorization of such <span class=\"match\">treatment</span>; and, (5) establishes a procedure that will ensure"},{"title":"Privacy Act of 1974; System of Records","type":"Notice","abstract":"Pursuant to the Privacy Act of 1974, notice is hereby given that VA is modifying the system of records titled \"Patient Medical Records-VA\" (24VA10A7). This system is used for ongoing treatment of individuals and patients; documentation of treatment provided; payment; health care operations such as producing various management and patient follow-up reports; responding to patient and other inquiries; for epidemiological research and other health care related studies; statistical analysis, resource allocation, and planning; providing clinical and administrative support to patient medical care; and determining entitlement and eligibility for VA benefits.","document_number":"2026-13454","html_url":"https://www.federalregister.gov/documents/2026/07/02/2026-13454/privacy-act-of-1974-system-of-records","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-02/pdf/2026-13454.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13454.pdf?1782909925","publication_date":"2026-07-02","agencies":[{"raw_name":"DEPARTMENT OF VETERANS AFFAIRS","name":"Veterans Affairs Department","id":520,"url":"https://www.federalregister.gov/agencies/veterans-affairs-department","json_url":"https://www.federalregister.gov/api/v1/agencies/520","parent_id":null,"slug":"veterans-affairs-department"}],"excerpts":"pertaining to the individual's <span class=\"match\">medical</span>, surgical, psychiatric, dental, and/or psychological examination, evaluation, and/or <span class=\"match\">treatment</span> (\n e.g., \n information related to the chief complaint and history of present illness; information related to physical, diagnostic, therapeutic special examinations; clinical laboratory, pathology and x-ray findings; operations; <span class=\"match\">medical</span> history; medications prescribed and dispensed; <span class=\"match\">treatment</span> plan and progress; consultations; photographs taken for identification and <span class=\"match\">medical</span> <span class=\"match\">treatment</span>; education and research purposes;"},{"title":"Expansion of Buprenorphine Treatment via Telemedicine Encounter","type":"Rule","abstract":"The Drug Enforcement Administration and the Department of Health and Human Services are amending their regulations to expand the circumstances under which practitioners registered by the Drug Enforcement Administration are authorized to prescribe schedule III-V controlled substances approved by the Food and Drug Administration for the treatment of opioid use disorder via a telemedicine encounter, including an audio-only telemedicine encounter. Under these new regulations, after a practitioner reviews the patient's prescription drug monitoring program data for the state in which the patient is located during the telemedicine encounter, the practitioner may prescribe an initial six-month supply of such medications (split amongst several prescriptions totaling six calendar months) through audio-only means. Additional prescriptions can be issued under other forms of telemedicine as authorized under the Controlled Substances Act, or after an in-person medical evaluation is conducted. This regulation also requires the pharmacist to verify the identity of the patient prior to filling a prescription. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in- person medical evaluation prior to issuance of a controlled substance prescription. However, this regulation falls under one of the exceptions found within the Ryan Haight Act. Additionally, this regulation does not affect practitioner-patient relationships in cases where an in-person medical evaluation has previously occurred. The purpose of this regulation is to prevent lapses of care by continuing some of the telemedicine flexibilities that currently exist for those patients seeking treatment for opioid use disorder.","document_number":"2025-01049","html_url":"https://www.federalregister.gov/documents/2025/01/17/2025-01049/expansion-of-buprenorphine-treatment-via-telemedicine-encounter","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-17/pdf/2025-01049.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-01049.pdf?1736948756","publication_date":"2025-01-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"},{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"receiving proper <span class=\"match\">treatment</span>, DEA published regulations in October 1974 to implement the Narcotic Addict <span class=\"match\">Treatment</span> Act of 1974 (NATA), authorizing practitioners to administer and dispense <span class=\"match\">certain</span> narcotic controlled substances, like methadone (schedule II) for detoxification <span class=\"match\">treatment</span> or maintenance <span class=\"match\">treatment</span> as long as the practitioners were separately registered as a narcotic <span class=\"match\">treatment</span> program (NTP or Opioid <span class=\"match\">Treatment</span> Program (OTP) as termed by SAMHSA).\n 29 \n \n The Drug Addiction <span class=\"match\">Treatment</span> Act of 2000 (DATA) further expanded <span class=\"match\">treatment</span> options for OUD"},{"title":"Clarifying Interstate Transportation of Firearms Under the Gun Control Act","type":"Proposed Rule","abstract":"The Bureau of Alcohol, Tobacco, Firearms, and Explosives (\"ATF\") proposes amending Department of Justice (\"Department\") regulations to clarify that, for purposes of transporting firearms interstate, any activities that are reasonably necessary to transportation such as staying overnight in temporary lodging, stopping for food, fuel, vehicle maintenance, an emergency, or medical treatment, or transiting between modes of transportation, are considered \"transport\" and thus protected by the Gun Control Act provision that addresses interstate transport of firearms. The proposed rule also addresses transporting ammunition and firearm accessories between states and the requirements for securing firearms during such transit.","document_number":"2026-08916","html_url":"https://www.federalregister.gov/documents/2026/05/06/2026-08916/clarifying-interstate-transportation-of-firearms-under-the-gun-control-act","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-06/pdf/2026-08916.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08916.pdf?1777985128","publication_date":"2026-05-06","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Bureau of Alcohol, Tobacco, Firearms, and Explosives","name":"Alcohol, Tobacco, Firearms, and Explosives Bureau","id":19,"url":"https://www.federalregister.gov/agencies/alcohol-tobacco-firearms-and-explosives-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/19","parent_id":268,"slug":"alcohol-tobacco-firearms-and-explosives-bureau"}],"excerpts":"Justice (“Department”) \n \n regulations to clarify that, for purposes of transporting firearms interstate, any activities that are reasonably necessary to transportation such as staying overnight in temporary lodging, stopping for food, fuel, vehicle maintenance, an <span class=\"match\">emergency</span>, or <span class=\"match\">medical</span> <span class=\"match\">treatment</span>, or transiting between modes of transportation, are considered “transport” and thus protected by the Gun Control Act provision that addresses interstate transport of firearms. The proposed rule also addresses transporting ammunition and firearm accessories between"},{"title":"Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Emergency Use Authorization of Medical Products","type":"Notice","abstract":"The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.","document_number":"2025-20771","html_url":"https://www.federalregister.gov/documents/2025/11/24/2025-20771/agency-information-collection-activities-submission-for-office-of-management-and-budget-review","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-11-24/pdf/2025-20771.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-20771.pdf?1763732728","publication_date":"2025-11-24","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"response activities involving <span class=\"match\">certain</span> FDA approved products without requiring FDA to issue an EUA and set forth <span class=\"match\">emergency</span> dispensing order and expiration date extension authority. \n \n The guidance document entitled, “<span class=\"match\">Emergency</span> Use Authorization of <span class=\"match\">Medical</span> Products and Related Authorities” (January 2017), available for download from our website at \n https://www.fda.gov/regulatory-information/search-fda-guidance-documents/<span class=\"match\">emergency</span>-use-authorization-<span class=\"match\">medical</span>-products-and-related-authorities, \n discusses FDA issuance of <span class=\"match\">Emergency</span> Use Authorizations (EUAs)"},{"title":"Trichloroethylene; Regulation Under the Toxic Substances Control Act (TSCA); Compliance Date Extension","type":"Rule","abstract":"The Environmental Protection Agency (EPA or Agency) is taking interim final action on the Regulation of Trichloroethylene (TCE) under the Toxic Substances Control Act (TSCA) to revise certain compliance deadlines finalized in 2024. Specifically, EPA is amending the prohibition compliance date for the use of TCE as a processing aid in the manufacture of nuclear fuel, with corresponding changes to the compliance dates for the manufacturing, processing and distribution in commerce of TCE to support such use, to a prohibition on September 15, 2028. EPA is also amending the prohibition compliance date for the disposal of TCE to wastewater by processors of TCE and processors and industrial and commercial users of TCE as a processing aid, to begin on December 18, 2026. EPA is also amending the compliance deadline for downstream notification, and the text required to be present in Safety Data Sheets, to accurately reflect the new prohibition compliance deadline for TCE used as a processing aid in the manufacture of nuclear fuel. EPA is amending this compliance deadline to allow for 90 days after the publication of the final rule for manufacturers, processors, and distributors in commerce of TCE to make such a change. These revisions are necessary to address new information presented to EPA about inadvertent oversights in the original rulemaking and serious concerns that the facilities at issue will be unable to comply with the relevant requirements by the existing deadlines. EPA is requesting comments on all aspects of this interim final rule and will consider all comments received in determining whether amendments to this rule are appropriate after the conclusion of the comment period.","document_number":"2025-17948","html_url":"https://www.federalregister.gov/documents/2025/09/17/2025-17948/trichloroethylene-regulation-under-the-toxic-substances-control-act-tsca-compliance-date-extension","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-09-17/pdf/2025-17948.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-17948.pdf?1757967310","publication_date":"2025-09-17","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"disposal of TCE to industrial pre-<span class=\"match\">treatment</span>, <span class=\"match\">treatment</span>, or to a publicly owned <span class=\"match\">treatment</span> works occurs must comply with the Workplace Chemical Protection Program provisions in § 751.315, except for the disposal permitted in § 751.305(b)(9). \n \n (h) Except for those uses specified in paragraphs (b), (c), and (d) of this section, all persons engaged in the uses specified in paragraphs (h)(i) or (ii) of this section are prohibited from disposal of TCE to industrial pre-<span class=\"match\">treatment</span>, industrial <span class=\"match\">treatment</span>, or publicly owned <span class=\"match\">treatment</span> works after December 18, 2026:"},{"title":"Methylene Chloride; Regulation Under the Toxic Substances Control Act (TSCA); Compliance Date Extensions","type":"Proposed Rule","abstract":"The Environmental Protection Agency (EPA or Agency) is proposing to extend the compliance date applicable to certain entities subject to the regulation of methylene chloride recently promulgated under the Toxic Substances Control Act (TSCA). Specifically, EPA is proposing to extend by 18 months the Workplace Chemical Protection Program (WCPP) and the associated recordkeeping compliance dates for laboratories that are not owned or operated by agencies or Federal contractors acting on behalf of the Federal government. Under this proposal, all laboratories, whether federal or not, would have the same compliance dates, which would be aligned with current compliance dates for Federal agencies and Federal contractors. EPA is proposing to extend the compliance dates for associated laboratory activities detailed in this proposal to avoid disruption of important functions such as the use of environmental monitoring methods needed for cleanup sites and wastewater treatment, as well as activities associated with university laboratories. The use of environmental monitoring methods, a common function of non-federal laboratories, is important to EPA's mission to ensure that the air is safe to breathe, water is safe for drinking or recreating, and disposal activities protect the environment.","document_number":"2025-09421","html_url":"https://www.federalregister.gov/documents/2025/05/27/2025-09421/methylene-chloride-regulation-under-the-toxic-substances-control-act-tsca-compliance-date-extensions","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-05-27/pdf/2025-09421.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-09421.pdf?1748004316","publication_date":"2025-05-27","agencies":[{"raw_name":"ENVIRONMENTAL PROTECTION AGENCY","name":"Environmental Protection Agency","id":145,"url":"https://www.federalregister.gov/agencies/environmental-protection-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/145","parent_id":null,"slug":"environmental-protection-agency"}],"excerpts":"newly proposed <span class=\"match\">compliance</span> dates are practicable and represent a reasonable transition period under TSCA section 6(d). Moreover, using <span class=\"match\">compliance</span> dates already established for Federal agencies and their contractors avoids the confusion that EPA may have created by having multiple <span class=\"match\">compliance</span> dates for various WCPP provisions. \n EPA requests comments and specific information addressing: \n • The ability of the various laboratories to comply with the requirements of the WCPP by the newly proposed <span class=\"match\">compliance</span> dates. \n • Alternative <span class=\"match\">compliance</span> timeframes for"},{"title":"Prohibition on Creditors and Consumer Reporting Agencies Concerning Medical Information (Regulation V)","type":"Rule","abstract":"The Consumer Financial Protection Bureau (CFPB) is issuing a final rule amending Regulation V, which implements the Fair Credit Reporting Act (FCRA), concerning medical information. The FCRA prohibits creditors from considering medical information in credit eligibility determinations. The CFPB is removing a regulatory exception that had permitted creditors to obtain and use information on medical debts notwithstanding this statutory limitation. The final rule also provides that a consumer reporting agency generally may not furnish to a creditor a consumer report containing information on medical debt that the creditor is prohibited from using.","document_number":"2024-30824","html_url":"https://www.federalregister.gov/documents/2025/01/14/2024-30824/prohibition-on-creditors-and-consumer-reporting-agencies-concerning-medical-information-regulation-v","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-01-14/pdf/2024-30824.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-30824.pdf?1736775917","publication_date":"2025-01-14","agencies":[{"raw_name":"Consumer Financial Protection Bureau","name":"Consumer Financial Protection Bureau","id":573,"url":"https://www.federalregister.gov/agencies/consumer-financial-protection-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/573","parent_id":null,"slug":"consumer-financial-protection-bureau"}],"excerpts":"IV.B.1, \n <span class=\"match\">Medical</span> Information Related to Debts, \n the CFPB finalizes its definition of <span class=\"match\">medical</span> debt information in final § 1022.3(j), as <span class=\"match\">medical</span> information that pertains to a debt owed by a consumer to a person whose primary business is providing <span class=\"match\">medical</span> services, products, or devices (also referred to herein as a health care provider), or to the person's agent or assignee, for the provision of such <span class=\"match\">medical</span> services, products, or devices. The definition also provides that <span class=\"match\">medical</span> debt information includes, but is not limited to, <span class=\"match\">medical</span> bills that"},{"title":"Reproductive Health Services","type":"Rule","abstract":"The Department of Veterans Affairs (VA) adopts as final, without changes, a proposed rule to reinstate the exclusions on abortions and abortion counseling from the medical benefits package, which were removed in 2022. Before 2022, these exclusions had been firmly in place since the medical benefits package was first established in 1999. VA is also adopting as final, without changes, the reinstatement of exclusions on abortion and abortion counseling for the Civilian Health and Medical Program of the Department of Veterans Affairs (CHAMPVA) that were also removed in 2022. VA takes this action to ensure that VA provides only needed and medically necessary and appropriate care to our nation's heroes and CHAMPVA beneficiaries.","document_number":"2025-24061","html_url":"https://www.federalregister.gov/documents/2025/12/31/2025-24061/reproductive-health-services","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-31/pdf/2025-24061.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-24061.pdf?1767102313","publication_date":"2025-12-31","agencies":[{"raw_name":"DEPARTMENT OF VETERANS AFFAIRS","name":"Veterans Affairs Department","id":520,"url":"https://www.federalregister.gov/agencies/veterans-affairs-department","json_url":"https://www.federalregister.gov/api/v1/agencies/520","parent_id":null,"slug":"veterans-affairs-department"}],"excerpts":"hospital with an <span class=\"match\">emergency</span> department, if any individual comes to the hospital or its campus and a request is made on behalf of the individual for examination or <span class=\"match\">treatment</span> for a <span class=\"match\">medical</span> condition, the hospital must provide for an appropriate <span class=\"match\">medical</span> screening examination within the capability of the <span class=\"match\">emergency</span> department, including ancillary services routinely available to the <span class=\"match\">emergency</span> department, to determine whether or not an <span class=\"match\">emergency</span> <span class=\"match\">medical</span> condition exists. It further requires that if any such individual has an <span class=\"match\">emergency</span> <span class=\"match\">medical</span> condition, the"},{"title":"Medications for the Treatment of Opioid Use Disorder","type":"Rule","abstract":"This final rule modifies and updates certain provisions of regulations related to Opioid Treatment Program (OTP) accreditation, certification, and standards for the treatment of Opioid Use Disorder (OUD) with Medications for Opioid Use Disorder (MOUD) in OTPs. This includes making flexibilities put forth during the COVID-19 Public Health Emergency (PHE) permanent, as well as expanding access to care and evidence-based treatment for OUD. The final rule also removes all language and rules pertaining to the Drug Addiction and Treatment Act (DATA) Waiver from the regulations pursuant to the \"Consolidated Appropriations Act, 2023\".","document_number":"2024-01693","html_url":"https://www.federalregister.gov/documents/2024/02/02/2024-01693/medications-for-the-treatment-of-opioid-use-disorder","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-02-02/pdf/2024-01693.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-01693.pdf?1706807349","publication_date":"2024-02-02","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Office of the Secretary"}],"excerpts":"rule modifies and updates <span class=\"match\">certain</span> provisions of regulations related to Opioid <span class=\"match\">Treatment</span> Program (OTP) accreditation, certification, and standards for the <span class=\"match\">treatment</span> of Opioid Use Disorder (OUD) with Medications for Opioid Use Disorder (MOUD) in OTPs. This includes making flexibilities put forth during the COVID-19 Public Health <span class=\"match\">Emergency</span> (PHE) permanent, as well as expanding access to care and evidence-based <span class=\"match\">treatment</span> for OUD. The final rule also removes all language and rules pertaining to the Drug Addiction and <span class=\"match\">Treatment</span> Act (DATA) Waiver from the"},{"title":"Health Care Professionals Practicing Via Telehealth","type":"Rule","abstract":"The Department of Veterans Affairs (VA) adopts as final, with changes, a proposed rule to amend its medical regulations that govern VA's health care professionals who practice health care via telehealth. This final rule implements the authorities of the VA MISSION Act of 2018 and the William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021. This final rule enables VA to maximize health care resource utilization and provide safe and convenient national health care to veterans using telehealth. It also strengthens VA's role in supporting national and State responses to war, terrorism, national emergencies and natural disasters.","document_number":"2025-19324","html_url":"https://www.federalregister.gov/documents/2025/10/02/2025-19324/health-care-professionals-practicing-via-telehealth","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-10-02/pdf/2025-19324.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-19324.pdf?1759322726","publication_date":"2025-10-02","agencies":[{"raw_name":"DEPARTMENT OF VETERANS AFFAIRS","name":"Veterans Affairs Department","id":520,"url":"https://www.federalregister.gov/agencies/veterans-affairs-department","json_url":"https://www.federalregister.gov/api/v1/agencies/520","parent_id":null,"slug":"veterans-affairs-department"}],"excerpts":"examination or <span class=\"match\">treatment</span> for a <span class=\"match\">medical</span> condition, the hospital must provide for an appropriate <span class=\"match\">medical</span> screening examination within the capability of the <span class=\"match\">emergency</span> department, including ancillary services routinely available to the <span class=\"match\">emergency</span> department, to determine whether or not an <span class=\"match\">emergency</span> <span class=\"match\">medical</span> condition exists. Lastly, under section 1785, VA may, during and immediately following a disaster or <span class=\"match\">emergency</span>, furnish hospital care and <span class=\"match\">medical</span> services to individuals responding to, involved in, or otherwise affected by that disaster or <span class=\"match\">emergency</span>. In conjunction"},{"title":"Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Humanitarian Use Devices","type":"Notice","abstract":"The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection related to humanitarian use devices (HUDs) and humanitarian device exemption (HDE).","document_number":"2025-14945","html_url":"https://www.federalregister.gov/documents/2025/08/07/2025-14945/agency-information-collection-activities-proposed-collection-comment-request-medical-devices","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-08-07/pdf/2025-14945.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-14945.pdf?1754484337","publication_date":"2025-08-07","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Portal (\n https://www.fda.gov/<span class=\"match\">medical</span>-devices/industry-<span class=\"match\">medical</span>-devices/send-and-track-<span class=\"match\">medical</span>-device-premarket-submissions-online-cdrh-portal \n ). Instructions and information regarding eCopy submission are available on FDA's website at \n \n https://www.fda.gov/<span class=\"match\">medical</span>-\n \n devices/how-study-and-market-your-device/ecopy-<span class=\"match\">medical</span>-device-submissions\n \n and in the FDA guidance document, “eCopy Program for <span class=\"match\">Medical</span> Device Submissions” (\n https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ecopy-program-<span class=\"match\">medical</span>-device-submissions \n ).\n "},{"title":"Current Good Manufacturing Practice, Certification, Postmarketing Safety Reporting, and Labeling Requirements for Certain Medical Gases","type":"Rule","abstract":"The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule revising the requirements concerning current good manufacturing practice (CGMP), postmarketing safety reporting, and labeling that apply to certain medical gases. This final rule also establishes regulations regarding certification of designated medical gases. This final rule satisfies the medical gas rulemaking requirements of the Consolidated Appropriations Act, 2017.","document_number":"2024-13190","html_url":"https://www.federalregister.gov/documents/2024/06/18/2024-13190/current-good-manufacturing-practice-certification-postmarketing-safety-reporting-and-labeling","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-06-18/pdf/2024-13190.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-13190.pdf?1718628314","publication_date":"2024-06-18","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"including the addition of <span class=\"match\">certain</span> operations required to produce a <span class=\"match\">medical</span> gas to the list of operations that are performed by its manufacturer. We are revising the requirements for stating the ingredients in the labeling of a designated <span class=\"match\">medical</span> gas or <span class=\"match\">medically</span> appropriate combination of designated <span class=\"match\">medical</span> gases (referred to hereafter in this preamble as “<span class=\"match\">medically</span> appropriate combination”).\n 1 \n \n We also specify \n \n requirements for the declaration of net quantity of contents in the labeling of designated <span class=\"match\">medical</span> gases and <span class=\"match\">medically</span> appropriate combinations"},{"title":"Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt","type":"Rule","abstract":"The Consumer Financial Protection Bureau (CFPB) is issuing this advisory opinion to remind debt collectors of their obligation to comply with the Fair Debt Collection Practices Act (FDCPA) and Regulation F's prohibitions on false, deceptive, or misleading representations or means in connection with the collection of any medical debt and unfair or unconscionable means to collect or attempt to collect any medical debts.","document_number":"2024-22962","html_url":"https://www.federalregister.gov/documents/2024/10/04/2024-22962/debt-collection-practices-regulation-f-deceptive-and-unfair-collection-of-medical-debt","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-10-04/pdf/2024-22962.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-22962.pdf?1727959529","publication_date":"2024-10-04","agencies":[{"raw_name":"Consumer Financial Protection Bureau","name":"Consumer Financial Protection Bureau","id":573,"url":"https://www.federalregister.gov/agencies/consumer-financial-protection-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/573","parent_id":null,"slug":"consumer-financial-protection-bureau"}],"excerpts":"\n The Burden of <span class=\"match\">Medical</span> Debt in the United State \n s, KFF (Feb. 12, 2024), \n https://www.kff.org/health-costs/issue-brief/the-burden-of-<span class=\"match\">medical</span>-debt-in-the-united-states/#:~:text=This%20analysis%20of%20government%20data,debt%20of%20more%20than%20%2410%2C000. \n \n \n \n \n 3 \n  CFPB, \n <span class=\"match\">Medical</span> Debt Burden in the United States \n at 2 (Mar. 1, 2022), \n https://www.consumerfinance.gov/data-research/research-reports/<span class=\"match\">medical</span>-debt-burden-in-the-united-states/. \n \n \n \n <span class=\"match\">Medical</span> debt is unique because consumers rarely plan to take on <span class=\"match\">medical</span> debt or choose among"}]}